Repros Therapeutics Offers Update on EU Submission of Enclomiphene for Treatment of Secondary Hypogonadism, 3-Month Interim Results for Enclomiphene Study
June 01, 2016 at 16:03 PM EDT
Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced that it remains on track for submission of a European centralized marketing ...